HMG-CoA reductase inhibitor, tea polyphenols and pancreatic cancer prevention

HMG-CoA还原酶抑制剂、茶多酚与胰腺癌预防

基本信息

  • 批准号:
    7434507
  • 负责人:
  • 金额:
    $ 21.14万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-06-01 至 2009-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The objective of this project is to study the mechanism-based chemoprevention of pancreatic carcinogenesis by HMG-CoA reductase inhibitor Lipitor and its combination with polyphenol E (a standardized tea polyphenol preparation). Our central hypothesis is that the inhibition of K-ras oncogene-driven pancreatic carcinogenesis by Lipitor is through targeting the mevalonate metabolic pathway, in particular via inhibiting prenylation and dolichylation on k-ras, lamins and IGF-1R proteins; the synergistic or additive effects on prevention of pancreatic carcinogenesis by the combination of Lipitor and polyphenol E will be produced through inhibition of arachidonic acid metabolits and down-stream signals of the K-ras pathway (such as ErK1/2 and c-Jun protein phosphorylation). We will test this hypothesis using a genetically engineered mouse model of pancreatic cancer (compound endogenously and conditionally knocked-in mouse model: LSL-k- rasG12D/?Trigh doses, and combination with low dose, of each agent) to test whether the combination of agents produces synergistic or additive effects, in addition to the inhibitory effect of each agent on pancreatic carcinogenesis. 2. Test the hypothesis that targeting the mevalonate pathway, arachidonic acid metabolits, and K-ras downstream signals by the combination of Lipitor and polyphenol E are the key molecular mechanisms in the prevention of pancreatic carcinogenesis. The specimens generated from Specific Aim 1 will be further examined for activity of k-ras protein, Ras, and IGF-1R protein membranous bound, and k-ras downstream signals, lamin and arachidonic acid metabolites with the biochemical and immunochemical approaches to reveal the mechanism involved. Furthermore, in-depth mechanistic studies will be performed using the selected immortalized human pancreatic ductal epithelial cell line and its k-ras transformed cell line in vitro. Using a genetically engineered mouse model of molecular-mimic pancreas cancer combined with chemopreventive agents, this project will be significant in the development of efficient strategy for the prevention of pancreas cancer in human.
描述(由申请人提供):本项目的目的是研究HMG-CoA还原酶抑制剂立普妥及其与多酚E(一种标准化茶多酚制剂)联合应用对胰腺癌发生的基于机制的化学预防作用。我们的中心假设是立普妥抑制K-ras癌基因驱动的胰腺癌发生是通过靶向甲羟戊酸代谢途径,特别是通过抑制k-ras、核纤层蛋白和IGF-1 R蛋白的异戊烯化和长链化;立普妥和多酚E的组合对预防胰腺癌发生的协同或相加作用将通过抑制花生四烯酸代谢和降低K-ras通路的信号流(如ErK 1/2和c-Jun蛋白磷酸化)。我们将使用胰腺癌的基因工程小鼠模型(化合物内源性和条件性敲入小鼠模型:LSL-k-rasG 12 D/?每种药剂的高剂量和与低剂量的组合),以测试除了每种药剂对胰腺癌发生的抑制作用之外,药剂的组合是否产生协同或累加作用。2.验证立普妥和多酚E联合作用靶向甲羟戊酸途径、花生四烯酸代谢产物和K-ras下游信号是预防胰腺癌发生的关键分子机制的假设。将用生化和免疫化学方法进一步检查特异性Aim 1产生的标本的k-ras蛋白、Ras和IGF-1 R蛋白膜结合活性,以及k-ras下游信号、核纤层蛋白和花生四烯酸代谢产物,以揭示相关机制。此外,将在体外使用所选择的永生化人胰腺导管上皮细胞系及其k-ras转化细胞系进行深入的机制研究。本研究通过建立分子模拟胰腺癌的基因工程小鼠模型,并结合化学预防药物,为胰腺癌的预防提供了有效的策略。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-KrasG12D-LSL-Trp53R172H-Pdx1-Cre mice.
  • DOI:
    10.1002/mc.21916
  • 发表时间:
    2013-09
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Liao, Jie;Chung, Yeon T.;Yang, Allison L.;Zhang, Meng;Li, Haonan;Zhang, Wanying;Yan, Liang;Yang, Guang-Yu
  • 通讯作者:
    Yang, Guang-Yu
CAAX-box protein, prenylation process and carcinogenesis.
Knockdown or inhibition of aldo-keto reductase 1B10 inhibits pancreatic carcinoma growth via modulating Kras-E-cadherin pathway.
  • DOI:
    10.1016/j.canlet.2014.09.031
  • 发表时间:
    2014-12-28
  • 期刊:
  • 影响因子:
    9.7
  • 作者:
    Zhang, Wanying;Li, Haonan;Yang, Yihe;Liao, Jie;Yang, Guang-Yu
  • 通讯作者:
    Yang, Guang-Yu
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Guang-Yu Yang其他文献

Guang-Yu Yang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Guang-Yu Yang', 18)}}的其他基金

Omega-3 derived epoxy fatty acids and sEH in pancreatitis-induced carcinogenesis
Omega-3 衍生的环氧脂肪酸和 sEH 在胰腺炎诱发的癌变中的作用
  • 批准号:
    9253390
  • 财政年份:
    2016
  • 资助金额:
    $ 21.14万
  • 项目类别:
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH
通过靶向 c-Raf 和 sEH 抑制胰腺癌发生
  • 批准号:
    8840908
  • 财政年份:
    2013
  • 资助金额:
    $ 21.14万
  • 项目类别:
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH
通过靶向 c-Raf 和 sEH 抑制胰腺癌发生
  • 批准号:
    8683133
  • 财政年份:
    2013
  • 资助金额:
    $ 21.14万
  • 项目类别:
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH
通过靶向 c-Raf 和 sEH 抑制胰腺癌发生
  • 批准号:
    8576766
  • 财政年份:
    2013
  • 资助金额:
    $ 21.14万
  • 项目类别:
Inhibition of pancreatic carcinogenesis via targeting c-Raf and sEH
通过靶向 c-Raf 和 sEH 抑制胰腺癌发生
  • 批准号:
    9056497
  • 财政年份:
    2013
  • 资助金额:
    $ 21.14万
  • 项目类别:
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
醛酮还原酶家族 1 成员 B10 AKR1B10 在胰腺癌发生中的作用
  • 批准号:
    8220421
  • 财政年份:
    2012
  • 资助金额:
    $ 21.14万
  • 项目类别:
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
醛酮还原酶家族 1 成员 B10 AKR1B10 在胰腺癌发生中的作用
  • 批准号:
    9093761
  • 财政年份:
    2012
  • 资助金额:
    $ 21.14万
  • 项目类别:
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
醛酮还原酶家族 1 成员 B10 AKR1B10 在胰腺癌发生中的作用
  • 批准号:
    8862423
  • 财政年份:
    2012
  • 资助金额:
    $ 21.14万
  • 项目类别:
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
醛酮还原酶家族 1 成员 B10 AKR1B10 在胰腺癌发生中的作用
  • 批准号:
    8527744
  • 财政年份:
    2012
  • 资助金额:
    $ 21.14万
  • 项目类别:
Aldo-keto reductase family 1 member B10 AKR1B10 in pancreatic carcinogenesis
醛酮还原酶家族 1 成员 B10 AKR1B10 在胰腺癌发生中的作用
  • 批准号:
    8682793
  • 财政年份:
    2012
  • 资助金额:
    $ 21.14万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 21.14万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了